$17.08
Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance Biopharma Swings to Net Loss in Q2, Revenue Falls
Theravance Bio: Q2 Earnings Snapshot
Overview
52-week range
$13
$21
50% of range
Avg surprise (last 3)
+176.0%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
20%
EM ±3.2% · $18 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.11 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.06 | $-0.06 | 0.0% | +77.8% | +0.5% | earnings |
| Tue Aug 12, 2025 | Jun/2025 | $1.08 | $-0.25 | +532.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.27 | $-0.26 | -3.9% | — | -0.9% | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | $18M | — | — | $26M | $15M | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | $-9M | — | — | $-3M | $-14M | — | — |
| Net income | $-6M | $-5M | — | — | $55M | $-14M | — | — |
| EPS (diluted) | $-0.11 | $-0.10 | — | — | $1.08 | $-0.27 | — | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $220M | $288M | $168M | $175M | $282M | $111M | $38M | $23M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $417M | $418M | $418M | $355M | $366M | $150M | $161M | $116M |
| Total assets | $470M | $472M | $486M | $415M | $426M | $344M | $354M | $356M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $290M | $291M | $297M | $233M | $225M | $166M | $176M | $186M |